OrthoPediatrics Corp. (NASDAQ:KIDS) Shares Bought by Kennedy Capital Management LLC

Kennedy Capital Management LLC lifted its position in OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 129.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 249,978 shares of the company's stock after acquiring an additional 141,174 shares during the quarter. Kennedy Capital Management LLC owned approximately 1.03% of OrthoPediatrics worth $5,794,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of KIDS. Wellington Management Group LLP raised its stake in shares of OrthoPediatrics by 16.2% during the 3rd quarter. Wellington Management Group LLP now owns 883,221 shares of the company's stock valued at $23,944,000 after purchasing an additional 122,846 shares during the period. Barclays PLC raised its position in OrthoPediatrics by 319.3% in the 3rd quarter. Barclays PLC now owns 25,298 shares of the company's stock worth $686,000 after purchasing an additional 19,264 shares during the period. Geode Capital Management LLC boosted its stake in shares of OrthoPediatrics by 2.1% during the third quarter. Geode Capital Management LLC now owns 391,492 shares of the company's stock valued at $10,615,000 after purchasing an additional 7,972 shares during the period. BNP Paribas Financial Markets increased its position in shares of OrthoPediatrics by 125.1% in the third quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company's stock valued at $94,000 after acquiring an additional 1,929 shares during the period. Finally, HighTower Advisors LLC purchased a new stake in OrthoPediatrics in the 4th quarter worth approximately $268,000. Hedge funds and other institutional investors own 69.05% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts have weighed in on KIDS shares. Lake Street Capital began coverage on OrthoPediatrics in a report on Monday, April 7th. They set a "buy" rating and a $37.00 target price on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $42.00 price target on shares of OrthoPediatrics in a research note on Wednesday, April 9th. Truist Financial lowered their price objective on shares of OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating on the stock in a research note on Friday. Finally, Stifel Nicolaus lowered their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, March 5th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, OrthoPediatrics currently has a consensus rating of "Moderate Buy" and a consensus target price of $37.00.

OrthoPediatrics Trading Down 0.0 %

KIDS traded down $0.01 during trading on Tuesday, reaching $20.97. The company had a trading volume of 143,503 shares, compared to its average volume of 199,081. OrthoPediatrics Corp. has a 52 week low of $20.37 and a 52 week high of $35.99. The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19. The business has a 50 day simple moving average of $24.07 and a 200-day simple moving average of $24.68. The stock has a market cap of $509.30 million, a P/E ratio of -17.05 and a beta of 1.17.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last issued its earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The business had revenue of $52.67 million during the quarter, compared to analysts' expectations of $51.16 million. During the same period in the prior year, the business earned ($0.23) EPS. On average, equities analysts anticipate that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

Insider Activity at OrthoPediatrics

In other news, CEO David R. Bailey sold 6,620 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $164,573.20. Following the completion of the transaction, the chief executive officer now directly owns 319,155 shares in the company, valued at $7,934,193.30. This trade represents a 2.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Fred Hite sold 6,443 shares of OrthoPediatrics stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $160,172.98. Following the sale, the chief financial officer now owns 207,989 shares of the company's stock, valued at approximately $5,170,606.54. The trade was a 3.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,732 shares of company stock valued at $589,978 in the last ninety days. Corporate insiders own 31.80% of the company's stock.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.